Proactive: Race Oncology Receives FDA Orphan Drug Designation Extension For Bisantrene RC220

The United States Food and Drug Administration (FDA) has extended Orphan Drug Designation (ODD) to our proprietary formulation of bisantrene, RC220, for acute myeloid leukemia.

Race CEO Dr Daniel Tillett spoke with Proactive about this significant announcement and the commercial advantage that the ODD will bring to bisantrene.

Read the full report here.